Fig. 2From: Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AMLLeukemic stem cells analysis: Bone marrow cells were used to identify Lineage–ve, CD34 + , CD38 −, CD123 + , CD45RA + . IL1RAP + cells with multiparameter flow cytometry. Very few (< 1%) leukemic stem cells were found in remission samplesBack to article page